Jianlin Du

Clinical analysis of the risk factors of slow coronary flow

Shuang Xia, Songbai Deng, Yang Wang et al. · Heart and Vessels · 2011 · 63 citations

Cardiovascular Epidemiology, Cardiovascular Disease, Coronary Artery Disease +11

Antibodies Can Last for More Than 1 Year After SARS-CoV-2 Infection: A Follow-Up Study From Survivors of COVID-19

Kaihu Xiao, Haiyan Yang, Bin Liu et al. · Frontiers in Medicine · 2021 · 51 citations · Full text

A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin

Dan Ran, Hui-juan Nie, Gao Yulin et al. · International Journal of Cardiology · 2017 · 48 citations

Thrombosis, Cardiovascular Disease, Myocardial Infarction +7

RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2

Jiangjun Wei, Fangyan Tan, Xianglin Long et al. · European Journal of Pharmaceutical Sciences · 2023 · 38 citations · Full text

Hypertension, Renal Protective Effects, Transcriptome Signature +17

The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis

Xiaodong Jing, Xiao-Ming Wei, Songbai Deng et al. · Clinica Chimica Acta · 2015 · 29 citations

Percutaneous Coronary Intervention, Vascular Disease, High-density Lipoprotein +11